Wai Leng Chow
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wai Leng Chow has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Choon How How
Care and Health Integration, Changi General Hospital, Singapore 529889, Singapore
3 shared publications - Dieu Thi Thu Huynh
Abbott Nutrition Research and Development, Asia-Pacific Center, Singapore 138668, Singapore
3 shared publications - Geraldine Baggs
Abbott Nutrition, Research & Development, Columbus, OH 43219, USA
3 shared publications - Jeffery Oliver
Abbott Nutrition Research and Development, Columbus, OH 43219, USA
3 shared publications - Ngiap Chuan Tan
SingHealth Polyclinics, Singapore 150167, Singapore
3 shared publications - Samuel Teong Huang Chew
Department of Geriatric Medicine, Changi General Hospital, Singapore 529889, Singapore
3 shared publications
Latest Publications
- Open Access
- 3 June 2026
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 15 (7) , 1955-1976
Prior SGLT2 Inhibitor and Metformin Use and Risk of Long COVID in Type 2 Diabetes: A Nationwide Population-Based Cohort Study
Introduction Patients with type 2 diabetes mellitus (T2DM) are at increased risk of post-acute sequelae after COVID-19 (PASC). Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and metformin may have systemic benefits beyond glycemic control. We evaluated the impact of prior SGLT2i and metformin use on the risk of post-acute COVID-19 complications. Methods We conducted a retrospective, population-based cohort study using national healthcare claims databases, from July 1, 2021 to February 28, 2023. Cohorts were stratified based on SGLT2i or metformin, against patients had not received these medications. Overlap weighting was applied to adjust for baseline differences in demographics, vaccination status, comorbidities, and prior healthcare utilization. Competing-risks regression models were used to assess differences in the risk of long-COVID outcomes between 31 and 300 days post-infection. Results Among 71,698 patients with T2DM, 22,501 (31.4%) had prior SGLT2i use, and 66,792 (93.1%) had prior metformin use. Compared with non-SGLT2i users, patients treated with SGLT2i had a significantly lower risk of neurological sequelae (aHR = 0.60 [0.45–0.81]), particularly memory and cognitive impairment (aHR = 0.63 [0.41–0.98]). SGLT2i was also associated with a reduced risk of post-acute symptoms (aHR = 0.87 [0.77–0.99]). Metformin use was associated with significantly lower risk of composite post-acute outcomes (aHR = 0.80 [0.68–0.96]) and post-acute symptoms (aHR = 0.77 [0.63–0.93]). Amongst patients on metformin, the addition of SGLT2i further lowered the risk of neurological sequelae (aHR = 0.81 [0.71–0.93]) and composite symptoms (aHR 0.87 [0.76–0.99]). Conclusion SGLT2i and metformin use were associated with a lower risk of PASC and post-acute symptoms. There may be additional protective benefits when both agents are used concurrently.
- 3 June 2026
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 15 (7) , 1955-1976
Open AccessPrior SGLT2 Inhibitor and Metformin Use and Risk of Long COVID in Type 2 Diabetes: A Nationwide Population-Based Cohort Study
Introduction Patients with type 2 diabetes mellitus (T2DM) are at increased risk of post-acute sequelae after COVID-19 (PASC). Sodium-glucose cotransporter-2 inhibitors (SGLT2i) and metformin may have systemic benefits beyond glycemic control. We evaluated the impact of prior SGLT2i and metformin use on the risk of post-acute COVID-19 complications. Methods We conducted a retrospective, population-based cohort study using national healthcare claims databases, from July 1, 2021 to February 28, 2023. Cohorts were stratified based on SGLT2i or metformin, against patients had not received these medications. Overlap weighting was applied to adjust for baseline differences in demographics, vaccination status, comorbidities, and prior healthcare utilization. Competing-risks regression models were used to assess differences in the risk of long-COVID outcomes between 31 and 300 days post-infection. Results Among 71,698 patients with T2DM, 22,501 (31.4%) had prior SGLT2i use, and 66,792 (93.1%) had prior metformin use. Compared with non-SGLT2i users, patients treated with SGLT2i had a significantly lower risk of neurological sequelae (aHR = 0.60 [0.45–0.81]), particularly memory and cognitive impairment (aHR = 0.63 [0.41–0.98]). SGLT2i was also associated with a reduced risk of post-acute symptoms (aHR = 0.87 [0.77–0.99]). Metformin use was associated with significantly lower risk of composite post-acute outcomes (aHR = 0.80 [0.68–0.96]) and post-acute symptoms (aHR = 0.77 [0.63–0.93]). Amongst patients on metformin, the addition of SGLT2i further lowered the risk of neurological sequelae (aHR = 0.81 [0.71–0.93]) and composite symptoms (aHR 0.87 [0.76–0.99]). Conclusion SGLT2i and metformin use were associated with a lower risk of PASC and post-acute symptoms. There may be additional protective benefits when both agents are used concurrently.
- Open Access
Effects of Oral Nutritional Supplement with β-Hydroxy-β-methylbutyrate (HMB) on Biochemical and Hematological Indices in Community-Dwelling Older Adults at Risk of Malnutrition: Findings from the SHIELD Study
Malnutrition may result in abnormal biochemical and hematological indices. This planned prespecified analysis investigated the effects of a specialized oral nutritional supplement (ONS) on biochemical and hematological indices in community-dwelling older adults at risk of malnutrition. In the Strengthening Health in ELDerly through nutrition (SHIELD) study, 811 older adults aged 65 years and above took part in this randomized, double-blind, placebo-controlled, multi-center study. Participants were randomly allocated to either a complete and balanced specialized ONS (each serving provides 262 kcal, 10.5 g protein, 7.75 µg vitamin D3, and 0.74 g calcium β-hydroxy-β-methylbutyrate) and dietary counselling (intervention group) or a placebo and dietary counselling (placebo group). Both groups consumed study products twice a day for 180 days. Data were collected at baseline, day 90, and day 180. Blood analysis results at follow-up visits were analyzed using repeated measures analysis of covariance with adjustments for confounders. Overall, when compared with the placebo group, the intervention group showed significantly greater urea (6.0 mmol/L vs. 5.4 mmol/L, p < 0.001), urea to creatinine ratio (4.39 vs. 4.26, p < 0.001), prealbumin (24.9 mg/dL vs. 24.0 mg/dL, p < 0.001), vitamin B12 (480.0 pmol/L vs. 420.1 pmol/L, p < 0.001), and globulin levels (26.8 g/L vs. 26.5 g/L, p = 0.032). The intervention group also had a significantly higher absolute reticulocyte count (62.0 × 103/µL vs. 58.2 × 103/µL, overall p < 0.001) and mean platelet volume (10.0 fL vs. 9.9 fL, overall p = 0.003). Furthermore, significant improvements were seen in total protein at day 90 (71.7 g/L vs. 71.1 g/L, p = 0.017) and in absolute monocyte count at day 90 (0.50 × 103/µL vs. 0.47 × 103/µL, p = 0.009) in the intervention group. In conclusion, daily consumption of a specialized ONS for six months led to significant improvements in biochemical and hematological indices in community-dwelling older adults at risk of malnutrition.
Open AccessEffects of Oral Nutritional Supplement with β-Hydroxy-β-methylbutyrate (HMB) on Biochemical and Hematological Indices in Community-Dwelling Older Adults at Risk of Malnutrition: Findings from the SHIELD Study
Malnutrition may result in abnormal biochemical and hematological indices. This planned prespecified analysis investigated the effects of a specialized oral nutritional supplement (ONS) on biochemical and hematological indices in community-dwelling older adults at risk of malnutrition. In the Strengthening Health in ELDerly through nutrition (SHIELD) study, 811 older adults aged 65 years and above took part in this randomized, double-blind, placebo-controlled, multi-center study. Participants were randomly allocated to either a complete and balanced specialized ONS (each serving provides 262 kcal, 10.5 g protein, 7.75 µg vitamin D3, and 0.74 g calcium β-hydroxy-β-methylbutyrate) and dietary counselling (intervention group) or a placebo and dietary counselling (placebo group). Both groups consumed study products twice a day for 180 days. Data were collected at baseline, day 90, and day 180. Blood analysis results at follow-up visits were analyzed using repeated measures analysis of covariance with adjustments for confounders. Overall, when compared with the placebo group, the intervention group showed significantly greater urea (6.0 mmol/L vs. 5.4 mmol/L, p < 0.001), urea to creatinine ratio (4.39 vs. 4.26, p < 0.001), prealbumin (24.9 mg/dL vs. 24.0 mg/dL, p < 0.001), vitamin B12 (480.0 pmol/L vs. 420.1 pmol/L, p < 0.001), and globulin levels (26.8 g/L vs. 26.5 g/L, p = 0.032). The intervention group also had a significantly higher absolute reticulocyte count (62.0 × 103/µL vs. 58.2 × 103/µL, overall p < 0.001) and mean platelet volume (10.0 fL vs. 9.9 fL, overall p = 0.003). Furthermore, significant improvements were seen in total protein at day 90 (71.7 g/L vs. 71.1 g/L, p = 0.017) and in absolute monocyte count at day 90 (0.50 × 103/µL vs. 0.47 × 103/µL, p = 0.009) in the intervention group. In conclusion, daily consumption of a specialized ONS for six months led to significant improvements in biochemical and hematological indices in community-dwelling older adults at risk of malnutrition.
- Open Access
- 14 April 2022
- Published by MDPI AG in Medical Sciences Forum
- Vol. 9 (1) , 5
Temporal Relationship between Urinary HMB Levels and Muscle Health in Community-Dwelling Older Adults at Risk of Malnutrition
Beta-hydroxy-beta-methylbutyrate (HMB) is the natural metabolite of leucine. There are very few studies which report on the temporal relationship between HMB levels following supplementation and muscle health. The objectives of this study were: (1) to investigate the effect of oral nutritional supplement (ONS) containing HMB on urinary HMB levels and (2) to determine the association between changes in HMB levels and muscle health. Urinary HMB levels indicate long-term HMB intake because levels increase and reach steady state over time. Data for analysis were derived from the SHIELD study, which was a randomised, double-blind, placebo-controlled trial consisting of 811 community-dwelling older adults at risk of malnutrition in Singapore. Participants were randomly allocated to either ONS containing HMB (0.74 g calcium HMB per serving) or placebo. Both groups received dietary counselling and consumed study products twice a day for 180 days. Data were collected at baseline, as well as days 30, 90, and 180. ONS containing HMB significantly increased urinary HMB levels in the intervention group over 180 days compared to placebo (p < 0.0001). The changes in HMB levels in the intervention group were positively correlated with changes in the total balance test score at day 90, ASMI, the SPPB score, and the score for the five chair stands at day 180, and negatively correlated with time taken for five chair stands at day 180 (all p ≤ 0.0425). There were also tendencies of positive association between HMB levels and calf circumference at day 90 and fat free mass at day 180 (both p ≤ 0.0591). However, no such associations were seen in the placebo group for the same measures above (all p ≥ 0.2537). In conclusion, consuming ONS containing HMB in community-dwelling older adults at risk of malnutrition significantly increased urinary HMB levels and correlated with improved muscle health. Therefore, ONS containing HMB should be incorporated in interventions for older adults with poor muscle health.
- 14 April 2022
- Published by MDPI AG in Medical Sciences Forum
- Vol. 9 (1) , 5
Open AccessTemporal Relationship between Urinary HMB Levels and Muscle Health in Community-Dwelling Older Adults at Risk of Malnutrition
Beta-hydroxy-beta-methylbutyrate (HMB) is the natural metabolite of leucine. There are very few studies which report on the temporal relationship between HMB levels following supplementation and muscle health. The objectives of this study were: (1) to investigate the effect of oral nutritional supplement (ONS) containing HMB on urinary HMB levels and (2) to determine the association between changes in HMB levels and muscle health. Urinary HMB levels indicate long-term HMB intake because levels increase and reach steady state over time. Data for analysis were derived from the SHIELD study, which was a randomised, double-blind, placebo-controlled trial consisting of 811 community-dwelling older adults at risk of malnutrition in Singapore. Participants were randomly allocated to either ONS containing HMB (0.74 g calcium HMB per serving) or placebo. Both groups received dietary counselling and consumed study products twice a day for 180 days. Data were collected at baseline, as well as days 30, 90, and 180. ONS containing HMB significantly increased urinary HMB levels in the intervention group over 180 days compared to placebo (p < 0.0001). The changes in HMB levels in the intervention group were positively correlated with changes in the total balance test score at day 90, ASMI, the SPPB score, and the score for the five chair stands at day 180, and negatively correlated with time taken for five chair stands at day 180 (all p ≤ 0.0425). There were also tendencies of positive association between HMB levels and calf circumference at day 90 and fat free mass at day 180 (both p ≤ 0.0591). However, no such associations were seen in the placebo group for the same measures above (all p ≥ 0.2537). In conclusion, consuming ONS containing HMB in community-dwelling older adults at risk of malnutrition significantly increased urinary HMB levels and correlated with improved muscle health. Therefore, ONS containing HMB should be incorporated in interventions for older adults with poor muscle health.
- Open Access
- 14 April 2022
- Published by MDPI AG in Medical Sciences Forum
- Vol. 9 (1) , 4
Effects of Oral Nutritional Supplement with HMB on Biochemical and Haematological Indices in Community-Dwelling Older Adults at Risk of Malnutrition
Malnutrition is associated with abnormal biochemical and haematological indices in older adults. There are few studies examining the impact of nutrition intervention on the above indices in community-dwelling older adults at risk of malnutrition. The objective of this study was to investigate the effects of an oral nutritional supplement (ONS) containing beta-hydroxy-beta-methylbutyrate (HMB) on biochemical and haematological indices in community-dwelling older adults at risk of malnutrition. A total of 811 older adults aged 65 years and above took part in the Strengthening Health in ELDerly through nutrition (SHIELD) study. This was a randomised, double-blind, placebo-controlled, multi-centre study across four sites in Singapore. The participants were randomly allocated to one of the two treatments: ONSs containing either HMB or a placebo. Both groups received dietary counselling and consumed the study products twice a day for 180 days. The data were collected at baseline, on day 90, and on day 180. We previously reported that ONSs containing HMB significantly improved nutritional outcomes and muscle health. The current analyses showed that pre-albumin, urea, globulin, corrected calcium, potassium, and vitamin B12 levels were significantly greater in the intervention group compared to the placebo group over 180 days (all p ≤ 0.032). The mean platelet volume, reticulocyte absolute, and reticulocyte percentage were also significantly higher in the intervention group (all p ≤ 0.003). In addition, there were tendencies of significant improvement in the total protein, monocyte absolute, monocyte percentage, and eosinophil percentage (all p ≤ 0.095). These improvements are attributable to the consumption of the ONS containing HMB in the intervention group. In conclusion, daily consumption of ONS containing HMB for six months significantly improved biochemical and haematological indices in community-dwelling older adults at risk of malnutrition. Early intervention after the identification of malnutrition is essential to optimise the nutritional status and markers of haemopoiesis.
- 14 April 2022
- Published by MDPI AG in Medical Sciences Forum
- Vol. 9 (1) , 4
Open AccessEffects of Oral Nutritional Supplement with HMB on Biochemical and Haematological Indices in Community-Dwelling Older Adults at Risk of Malnutrition
Malnutrition is associated with abnormal biochemical and haematological indices in older adults. There are few studies examining the impact of nutrition intervention on the above indices in community-dwelling older adults at risk of malnutrition. The objective of this study was to investigate the effects of an oral nutritional supplement (ONS) containing beta-hydroxy-beta-methylbutyrate (HMB) on biochemical and haematological indices in community-dwelling older adults at risk of malnutrition. A total of 811 older adults aged 65 years and above took part in the Strengthening Health in ELDerly through nutrition (SHIELD) study. This was a randomised, double-blind, placebo-controlled, multi-centre study across four sites in Singapore. The participants were randomly allocated to one of the two treatments: ONSs containing either HMB or a placebo. Both groups received dietary counselling and consumed the study products twice a day for 180 days. The data were collected at baseline, on day 90, and on day 180. We previously reported that ONSs containing HMB significantly improved nutritional outcomes and muscle health. The current analyses showed that pre-albumin, urea, globulin, corrected calcium, potassium, and vitamin B12 levels were significantly greater in the intervention group compared to the placebo group over 180 days (all p ≤ 0.032). The mean platelet volume, reticulocyte absolute, and reticulocyte percentage were also significantly higher in the intervention group (all p ≤ 0.003). In addition, there were tendencies of significant improvement in the total protein, monocyte absolute, monocyte percentage, and eosinophil percentage (all p ≤ 0.095). These improvements are attributable to the consumption of the ONS containing HMB in the intervention group. In conclusion, daily consumption of ONS containing HMB for six months significantly improved biochemical and haematological indices in community-dwelling older adults at risk of malnutrition. Early intervention after the identification of malnutrition is essential to optimise the nutritional status and markers of haemopoiesis.